The enterprise plans to produce over 30 million doses of the drug annually.
According to TASS, the company’s president and chief executive Ruweida Dham said that the pharmaceutical company Arvan and the Russian Direct Investment Fund (RDIF) will sign an agreement on Tuesday, August 3, on the production of the Russian Sputnik V vaccine in Lebanon.
“The production of the Russian drug will be launched at Arvan’s pharmaceutical plant in Jadrah, south of Beirut”, – Dham said, adding that Lebanese President Michelle Aoun “strongly supports this project.”
Dham noted that the Lebanese company approached RDIF in March with a proposal to consider the possible production of Sputnik V in Lebanon.
“We sent the necessary technical documentation and entered into contacts with experts from the NF Gamaleya Center for Epidemiology and Microbiology,” she said.
According to the vice president, the company plans to produce over 30 million doses annually.
“Our company has already received requests for the Russian drug from neighboring countries, in particular, from Syria, Iraq and Egypt, so the volume of production may be increased in the future,” Dham emphasized.